ANIX Anixa Biosciences, Inc.
Financings ·
Anixa Biosciences filed a $200,000,000 replacement shelf on September 10, 2025, with a $100,000,000 sales program through Cantor Fitzgerald & Co., because its current shelf expires on September 19, 2025 and its clinical programs are still in early trials.
We have not published a story on Anixa Biosciences yet. When there is news, it will appear here.
Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines for critical unmet needs in oncology. Its therapeutics program is liraltagene autoleucel (lira-cel), a chimeric endocrine receptor T cell therapy, a novel form of CAR-T technology initially focused on ovarian cancer. It is developed at its subsidiary Certainty Therapeutics, Inc., which holds an exclusive worldwide, royalty-bearing license to technology owned or controlled by The Wistar Institute. Lira-cel is in a Phase 1 trial with the H. Lee Moffitt Cancer Center and Research Institute, a dose-escalation study in recurrent epithelial ovarian cancer. Its vaccine programs include a breast cancer vaccine, developed under a license from The Cleveland Clinic Foundation and focused initially on triple-negative breast cancer, and an ovarian cancer vaccine. The breast cancer vaccine's Phase 1 trial reached final data, presented on December 11, 2025. A vaccine discovery program aims to develop additional cancer vaccines for lung, colon and prostate malignancies.
| Product or program | What it is | Stage |
|---|---|---|
| Lira-cel (liraltagene autoleucel) | Chimeric endocrine receptor CAR-T therapy for ovarian cancer | Phase 1 |
| Breast cancer vaccine | Vaccine against alpha-lactalbumin for triple-negative breast cancer | Phase 1, final data presented |
| Ovarian cancer vaccine | Cancer vaccine for ovarian cancer |
| Line | FY ended Oct 31, 2025 | FY ended Oct 31, 2024 |
|---|---|---|
| Revenue | $210,000 | |
| Research and development | $5.1 million | $6.4 million |
| Net income (loss) | -$10.9 million | -$12.6 million |
| Cash from operations | -$7.2 million | -$7.3 million |
| Cash and equivalents | $1.2 million | $1.3 million |
| Short-term investments | $13.9 million | $18.7 million |
Our latest story on this, dated Sep 10, 2025: "Anixa Biosciences files $200,000,000 replacement shelf with $100,000,000 ATM". The story links the filing or release it is based on. Read the story.
Anixa Biosciences, Inc. trades under the ticker ANIX on NASDAQ.
Anixa Biosciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:CY71; LSX:A2N6ZF.
The SEC Central Index Key (CIK) for Anixa Biosciences, Inc. is 715446. Its filings are on SEC EDGAR.
34,763,802 shares as of 2026-09-09, per the cover page of its 10-Q filed 2026-09-09.
Our directory records Anixa Biosciences, Inc. under United States.
Our directory classifies Anixa Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Anixa Biosciences, Inc. is US03528H1095.
aibio.space lists Anixa Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines for critical unmet needs in oncology. Its therapeutics program is liraltagene autoleucel (lira-cel), a chimeric endocrine receptor T cell therapy, a novel form of CAR-T technology initially focused on ovarian cancer.
Lira-cel (liraltagene autoleucel): Chimeric endocrine receptor CAR-T therapy for ovarian cancer Stage: Phase 1.
Breast cancer vaccine: Vaccine against alpha-lactalbumin for triple-negative breast cancer Stage: Phase 1, final data presented.
Anixa Biosciences, Inc. reported a net loss of $10.9 million for the fiscal year ended Oct 31, 2025, and used $7.2 million of cash in operations, per its annual report to the SEC.
$5.1 million in the fiscal year ended Oct 31, 2025, per its annual report.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio